Cystic fibrosis breakthrough has given patients a chance to live longer

Personal Experiences with CF and Trikafta

• Multiple commenters lost friends or relatives to CF, often in their teens or 20s, sometimes even after lung transplants.
• Several people with CF report Trikafta as life‑changing: no more annual hospitalizations, far fewer infections, and lung function stabilized at levels that previously would have implied steep decline.
• Others with CF or transplant note they skipped Trikafta (e.g., after double‐lung transplant) because expected lung benefits were limited and weight gain might burden already fragile lungs.
• Timing was noted as crucial: Trikafta arrived too late for many, which some describe as bittersweet or maddeningly unjust.

Psychological and Life‑Course Effects

• Some describe a “Lazarus syndrome”–like shift: going from preparing for early death to suddenly having a longer, uncertain future can trigger anxiety, depression, substance abuse, or major life changes.
• A few CF patients and others with chronic genetic diseases say their anxiety actually increased after effective treatment, because there is now more to lose and more life decisions to navigate.

Online Communities and Support

• Chronic illness forums are widely criticized as dominated by the most distressed members, with little focus on research and heavy presence of venting, conspiracism, and alternative‑medicine scams.
• People managing their disease relatively well tend not to participate, skewing the tone toward pessimism and conflict.

Side Effects and Unclear Causality

• Many CF patients report new or severe anxiety after starting Trikafta; some improve when dose is reduced or stopped.
• Clinicians, according to the discussion, say evidence for a direct causal link is lacking; this tension remains unresolved.
• Other drug examples (e.g., Accutane, orlistat) are used to illustrate how underlying disease and context can blur side‑effect attribution.

Weight Gain and Physiology

• Weight gain is a common downside: improved pancreatic function and reduced work of breathing mean patients absorb more calories and must “recalibrate” eating habits.
• This is a striking reversal for people long told to overeat to maintain weight; some now worry about obesity and diabetes.

Cost, Access, and Pharma Economics

• Trikafta’s list price (~$300k/year) is heavily debated.
• Some argue high prices and patents are necessary to fund risky, decade‑long R&D, praising Vertex and the U.S. system for making such drugs exist at all.
• Others emphasize inequity: uninsured or non‑U.S. patients may be left behind until patents expire or countries negotiate coverage.
• Patient‑assistance programs and copay support are reported as generous in practice, though dependence on insurers and “nameless bureaucrats” is unsettling.
• Comparisons are drawn with biologics like Humira (expensive even post‑patent) and cheaper small‑molecule generics, with Trikafta expected to fall into the latter category eventually.
• Some discuss “drug piracy”: sourcing active ingredients from abroad and compounding them, with informal testing via foreign labs, though this is framed as fringe and legally/medically risky.

Related Medical and Ethical Reflections

• CF advances are compared to the HIV drug revolution: transforming a terminal disease into a chronic one with complex psychological fallout.
• Some extend the discussion to gene therapy as an emerging reality and argue that similar effort should target aging itself, seen by some as a treatable “universal disease.”
• Others push back, distinguishing aging from specific pathologies like Alzheimer’s and cancer, and questioning societal priorities and taxpayer willingness to fund cures for rare diseases.
• Policy alternatives such as fully public drug development (no patents) are mentioned, with counter‑arguments that centralized government funding may be less efficient or more corruptible than market‑driven R&D.

Systems and Institutions

• Make‑A‑Wish no longer automatically qualifies CF patients due to improved prognosis, which some see as a sign of real progress but also as bureaucratically insensitive.
• Differences between U.S. and other health systems are highlighted: the U.S. often adopts expensive new drugs faster, while socialized systems negotiate harder or delay coverage due to budget limits.